NUTEX InvestmentsBUD:NUTEX -0.37%50 Quick Ratio is 155.53 as of Dec. 2025, which is 39% below its 10-year median of 254.23. GuruFocus rates BUD:NUTEX with a GF Score™ of 50/100 and a GF Value™ of Ft13.80 (Fairly Valued). The stock has 3 warning signs investors should review. Among 996 Drug Manufacturers companies, NUTEX Investments ranks better than 99.8% on this metric.
NUTEX Investments has a quick ratio of 155.53. It generally indicates good short-term financial strength.
The historical rank and industry rank for NUTEX Investments's Quick Ratio or its related term are showing as below:
BUD:NUTEX'
s Quick Ratio Range Over the Past 10 Years
Min: 0.15 Med: 254.23 Max: 876.72
Current: 155.53
During the past 13 years, NUTEX Investments's highest Quick Ratio was 876.72. The lowest was 0.15. And the median was 254.23.
BUD:NUTEX's Quick Ratio is ranked better than 99.8% of 996
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs BUD:NUTEX: 155.53
NUTEX Investments (BUD:NUTEX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
NUTEX Investments Quick Ratio Related Terms
NUTEX Investments Quick Ratio Historical Data
* Premium members only.
The historical data trend for NUTEX Investments's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUD:NUTEX vs ZTS, UTHR, VTRS: Quick Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, NUTEX Investments's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NUTEX Investments Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NUTEX Investments's Quick Ratio distribution charts can be found below:
* The bar in red indicates where NUTEX Investments's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
NUTEX Investments's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NUTEX Investments (BUD:NUTEX) has a Quick Ratio of 155.53 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on NUTEX Investments and its competitors. This is 39% below median its historical median of 254.23. Over the past decade, NUTEX Investments' Quick Ratio has ranged from 0.15 to 876.72. According to the industry distribution chart, NUTEX Investments ranks #2 out of 996 companies in the Drug Manufacturers industry, placing it in the top 0.2%.
Is NUTEX Investments' Quick Ratio too high?
NUTEX Investments' current Quick Ratio of 155.53 is 39% below median its 10-year median of 254.23. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 876.72. The Drug Manufacturers industry median Quick Ratio is 1.45. NUTEX Investments' value of 155.53 is 10626.2% above this industry median. Based on the distribution chart, NUTEX Investments ranks #2 out of 996 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, NUTEX Investments has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NUTEX Investments' Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, NUTEX Investments ranks #2 out of 996 companies for Quick Ratio. This places NUTEX Investments in the top 0% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. NUTEX Investments' value of 155.53 is 10626.2% above this benchmark. Historically, NUTEX Investments' own Quick Ratio has ranged from 0.15 to 876.72 over the past decade. While the company's 10-year median is 254.23 vs. the industry median of 1.45, NUTEX Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NUTEX Investments's current Quick Ratio of 155.53 is 10626.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on NUTEX Investments and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NUTEX Investments's current Quick Ratio is 155.53, which is 39% below median its own 10-year median of 254.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NUTEX Investments stock overvalued right now?
Based on GuruFocus' analysis, NUTEX Investments (BUD:NUTEX) is currently considered Fairly Valued. The stock's GF Value™ is Ft13.80, compared to a current price of Ft13.40 — trading 2.9% below its estimated fair value. The current Quick Ratio is 155.53, which is 39% below median its 10-year median of 254.23 and 10626.2% above the Drug Manufacturers industry median of 1.45. NUTEX Investments' overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For NUTEX Investments (BUD:NUTEX), the current Quick Ratio is 155.53 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NUTEX Investments (BUD:NUTEX) Overvalued in 2026?
Based on GuruFocus' analysis, NUTEX Investments stock appears to be undervalued.
The current stock price of Ft13.40 is trading 2.9% below its estimated GF Value™ of Ft13.80.
GuruFocus considers NUTEX Investments to be Fairly Valued.
Key valuation signals for BUD:NUTEX:
Quick Ratio: 155.53 (39% below median its 10-year median of 254.23)
GF Value™: Ft13.80 vs. price of Ft13.40 (2.9% below fair value)
Industry Position: 10626.2% above the Drug Manufacturers median (#2 of 996)
No single metric tells the full story. See the BUD:NUTEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NUTEX Investments PLC operates as a drug manufacturer in Hungary. The company is engaged in production of products that focuses on health, vitality, and natural ingredients.
50GF Score
Get the complete analysis for BUD:NUTEX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NUTEX has been successfully added to your 
